July 22, 2021 6:04pm

As I stated this a.m., “my internal Ouija board has lost its spirit. Expect a continuation of low volume trading through the seasonally-weak summer months and a more than possible correction”

Pre-open indications: 1 HIT as I also stated this a.m., “Call me neurotic as I feel the “Pac-Man” algorithms are “looking” for a taste of low volume upsides.”

My comments try to distinguish the temporary from real pricing digression or progress.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers! 

The Dow closed UP +28.38 points (+0.07%); the S&P closed UP +8.79 points (+0.20%) while the Nasdaq closed UP +52.84 points (+0.36%)

 

Henry’omics:

Indexes edged in a slim range on Thursday, with traders struggling to decipher the meaning behind a surprise rise in unemployment, which threatens a (two (2) session rally that wiped out Tuesday and Wednesday’s gains after Monday’s dismal sector “showing”.

Sentiment also took a hit after “jobs” data showed an unexpected jump in jobless claims, which last week set a fresh pandemic-era low. New unemployment filings jumped to 419,000 in the latest week, well above consensus estimates of 360,000.

Since the onset of COVID-19, the data series has served as an avatar of the labor market's health, and could take on new importance if rising infections start to trigger new restrictions — which may lead to another round of job losses. <Yahoo news>

 

RegMed Investors’ (RMi) pre-open: “my internal Ouija board has lost its spirit. Expect a continuation of low volume trading through the seasonally-weak summer months and a more than possible correction” … https://www.regmedinvestors.com/articles/12014

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened negative at 7/25, 2 flats and 1 acquired, stayed negative at the mid-day to 6/26, 2 flats and 1 acquired, closing negative 6/26, 2 flats and 1 acquired;

 

The Biostage (BSTG) Chronicles: Thursday closed flat with 200 shares traded after Wednesday closed +$0.01 to $1.71 with 200 shares traded, Tuesday’s volume of 49 shares with a flat outcome proves I am RIGHT re the “pump” promoting, Monday’s 207 shares traded dropping -$0.01 to $1.70, Friday’s +$0.01 with 307 shares traded (bought by whom) and last Thursday as 1,596 shares traded as with a close of -$0.01.

  • WHY the “push/promote”; it is to exercise warrants adding more unregistered shares to the “outstanding” which is BSTG’s ONLY vehicle to raise money for operation continuation – they’re BROKE – so the only runway access is ?

 

Pre-open Indications: 1 HIT <SELL: Biostage (BSTG +$0.00)>

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals IONS), BioLife Solutions (BLFS) - again, Fate Therapeutics (FATE) - again, Brainstorm Cell Therapeutics (BCLI) to name 6 of the 6 inclining of the 35

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Sage Therapeutics (SAGE), Vericel (VCEL), Ultragenyx (RARE) to name 5 of the 26 declining of the 35 covered

 

Key Metrics:

  • Sector volume was LOW with 1 of the 6-upside having higher than the 3-month average volume with very LOW volume of 3 of 26-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 6-upside were +0.16% (FATE) to +2.12% (IONS) while the 26-downside ranges from -0.90% (RGNX) to -9.41% (KDNY);

 

Thursday’s (6 of 6) incliners:

  • Alnylam Pharmaceuticals (ALNY +$1.72 after Wednesday’s -$3.08, Tuesday’s +$7.86 and Monday’s +$2.23);
  • BioLife Solutions (BLFS +$0.61 after Wednesday’s +$0.34, Tuesday’s +$1.79 and Monday’s -$0.67);
  • Fate Therapeutics (FATE +$0.14 after Wednesday’s +$1.77, Tuesday’s +$3.48 and Monday’s +$2.03);
  • Brainstorm Cell Therapeutics (BCLI +$0.01);
  • Athersys (ATHX +$0.01);

Thursday’s (10 of 26) decliners:

  • Intellia Therapeutics (NTLA -$4.87 after Wednesday’s +$6.63, Tuesday’s +$7.18 and Monday’s +$3.69);
  • CRISPR Therapeutics (CRSP -$3.68 after Wednesday’s +$4.31, Tuesday’s -$1.59);
  • Sage Therapeutics (SAGE -$1.74 after Wednesday’s +$0.62);
  • Vericel (VCEL -$1.55 after Wednesday’s +$2.04, Tuesday’s +$2.44 and Monday’s -$0.78);
  • Ultragenyx (RARE-$1.36 after Wednesday’s -$1.64, Tuesday’s +$2.29 after Monday’s -$1.07);
  • Chinook Therapeutics (KDNY -$1.36 after Wednesday’s -$0.17);
  • Global Blood Therapeutics (GBT -$1.10 after Wednesday’s -$0.06, Tuesday’s -$0.08 and Monday’s -$1.19);
  • Editas Medicine (EDIT -$1.08 after Wednesday’s +$0.64, Tuesday’s -$0.15 and Monday’s +$1.21);
  • uniQure NV (QURE -$0.63);
  • Cellectis SA (CLLS -$0.53 after Wednesday’s +$0.38);

Closing – 2 flat – Biostage (BSTG), ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +0.26% and XBI closed down -1.26%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.22 points or -1.23% at 17.69

Upside volume:

  • Thursday: 1 out of the 6-upside had higher than the 3-month average volume;

Downside volume:

  • Thursday: 3 out of the 26-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Thursday’s percentage (%) of the 6-upside were +0.16% (FATE) to +2.12% (IONS) while the 26-downside ranges from -0.90% (RGNX) to -9.41% (KDNY);

 

July, first month of Q3/21:

Thursday closed negative with 6 advancers, 26 decliners, 2 flats and 1 acquired

Wednesday closed positive with 27 advancers, 7 decliners and 1 acquired

Tuesday closed positive with 29 advancers, 4 decliners, 1 flat and 1 acquired

Monday (7/19) closed negative with 4 advancers, 30 decliners and 1 acquired

 

The BOTTOM LINE: Reiterating, “I’m still right … as I had stated, “I expect smaller and choppier gains, brace for more volatility.”

Sector share pricing was subjected to a negative headwind as I had stated, “the algorithmic “Pac-Mans” ate the upside”.

Adding some warning signs for investors – Q2 earnings on the horizon.

A tool that hasn’t resonated … guidance is one factor of the sector. NO news has bake- in the decline of the sector.

Keep an eye on “runways” … as quarterly earnings come out

The real issue is that Q2 earnings are going to “suck pond water”!

Next few months – unless, news of clinical results or an M&A after a choppy and marginal performance in the first half.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.